[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","oewxi56qmfi0wvxaf5gmdx8yy","revision",2,"title","Cardiol Therapeutics 提交 6-K，披露与 Jefferies LLC 的市场增发计划公告","originalTitle","6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)","summary","Cardiol Therapeutics 提交 Form 6-K，随附 11 月 3 日新闻稿，宣布与 Jefferies LLC 达成市场增发计划。公司按 Form 40-F 提交年度报告。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-11-03T22:15:45.000Z","discoveredAt","2026-11-04T04:34:47.198Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",39,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fmnMLix7f2X4",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","03fed462-abdc-4945-9d0d-02c590ef7cf8","Cardiol Therapeutics与Jefferies达成市场增发安排并提交相关文件",{"_72":73,"_15":74},"zh","

UNITED STATES
\nSECURITIES AND EXCHANGE COMMISSION
\nWashington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO\nRULE 13a-16 OR 15d-16
\nUNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-40712

Cardiol Therapeutics\nInc.
\n(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville,\nOntario, Canada L6H 0G5
\n(Address of principal executive offices)

Indicate by check mark whether the registrant\nfiles or will file annual reports under cover Form 20-F or Form 40-F.

[ ] Form 20-F [X]\nForm 40-F

SUBMITTED HEREWITH

Exhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit		Description

99.1		News Release dated November 3, 2026 - Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC

SIGNATURES

Pursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	CARDIOL THERAPEUTICS INC.
	(Registrant)

Date: November 3, 2026	By:	/s/ Christopher Waddick
		Christopher Waddick
	Title:	Chief Financial Officer

","zhKind","complete","CRDL","公司与财报","融资","aihot","/items/oewxi56qmfi0wvxaf5gmdx8yy","https://www.sec.gov/Archives/edgar/data/1702123/000127956926001022/0001279569-26-001022-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1794960000&sig=44baa70fbeef50e6","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1794960000&sig=a4957e0f65b84b31 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1794960000&sig=c50e8e83f0dcfb02 96w","changelogVersion","2026-10-01T08:00"]